IDiyas

For the Inventor, By the Inventor

Tsukuba, Japan

Takashi Hayama

USPTO Granted Patents = 16

Average Co-Inventor Count = 4.3

ph-index = 6

Forward Citations = 149(Granted Patents)


Location History:

  • Kawasaki, JP (1994)
  • Tokyo, JP (1992 - 1997)
  • Ibaraki, JP (2005 - 2006)
  • Tsukuba, JP (1995 - 2008)

Company Filing History:

goldMedal16 out of 237 
 
Banyu Pharmaceutical Co. Ltd
 patents

Years Active: 1992-2008

Loading Chart...
16 patents (USPTO):
1. 7354946 - Biarylurea derivatives (2008-04-08),
2. 7148224 - Pyrazinone derivatives (2006-12-12),
3. 6958333 - Biarylurea derivatives (2005-10-25),
4. 6914062 - Pyrazinone derivatives (2005-07-05),
5. 6413979 - Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative (2002-07-02),
6. 5714479 - Endothelin antagonistic heteroaromatic ring-fused cyclopentene (1998-02-03),
7. 5691315 - Endothelin antagonistic peptide derivatives (1997-11-25),
8. 5498717 - 6,7-dialkoxy-3,4-diydroisoquinolin-8-yl compounds (1996-03-12),
9. 5496928 - Endothelin antagonistic substance (1996-03-05),
10. 5470833 - Endothelin antagonistic peptide derivatives (1995-11-28),
11. 5446164 - Process for preparing 6,7-dialkoxy-3,4-dihydroisoquinolin-8-ol (1995-08-29),
12. 5444152 - Endothelin antagonistic peptide derivatives (1995-08-22),
13. 5389620 - Endothelin antagonistic heteroaromatic ring-fused cyclopentene (1995-02-14),
14. 5380921 - Aminophosponic acid derivative (1995-01-10),
15. 5362736 - Isoquinoline derivatives (1994-11-08),

Title: Takashi Hayama: Innovator in Pharmaceutical Chemistry

Introduction

Takashi Hayama is a prominent inventor based in Tsukuba, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target cancer treatment. With a total of 16 patents to his name, Hayama's work has the potential to impact the medical community significantly.

Latest Patents

Among his latest innovations are the biarylurea derivatives, which relate to a compound designed to inhibit Cdk4 and/or Cdk6 for treating malignant tumors. This compound exhibits notable growth inhibitory activity against tumor cells, showcasing its potential as a therapeutic agent. Another significant patent involves pyrazinone derivatives, which also serve as inhibitors of Cdk4 and/or Cdk6, further establishing Hayama's focus on anti-cancer agents. These compounds are not only innovative but also represent a step forward in the fight against cancer.

Career Highlights

Hayama is currently associated with Banyu Pharmaceutical Co. Ltd., where he continues to develop groundbreaking pharmaceutical solutions. His work has been instrumental in advancing the understanding and treatment of various cancers through innovative chemical compounds.

Collaborations

Throughout his career, Hayama has collaborated with notable colleagues such as Kiyofumi Ishikawa and Mitsuo Yano. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical products.

Conclusion

In summary, Takashi Hayama is a distinguished inventor whose work in pharmaceutical chemistry is paving the way for new cancer treatments. His innovative patents and collaborations highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…